Media Coverage
Pre-existing Immunogenicity: How Will Cell and Gene Therapies Change Our Testing Approach?
In this article, Chief Scientific Officer at BioAgilytix, Jim McNally, Ph.D., explores why bioanalysts should prepare for the impending wave of C>s entering the development pipeline and the considerations they must make in their pre-existing immunogenicity assessments.
![molecule 3d rendering](https://www.bioagilytix.com/wp-content/uploads/2023/06/Immunogenicity-image.jpg)